CN112236142A - 用于缓释递送丁丙诺啡的药物组合物 - Google Patents

用于缓释递送丁丙诺啡的药物组合物 Download PDF

Info

Publication number
CN112236142A
CN112236142A CN201980009501.7A CN201980009501A CN112236142A CN 112236142 A CN112236142 A CN 112236142A CN 201980009501 A CN201980009501 A CN 201980009501A CN 112236142 A CN112236142 A CN 112236142A
Authority
CN
China
Prior art keywords
buprenorphine
acid
pharmaceutical composition
amount
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980009501.7A
Other languages
English (en)
Chinese (zh)
Inventor
李雨华
李明欣
李成昶
杨佳颖
林芷莹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Foresee Pharmaceuticals Co Ltd
Original Assignee
Foresee Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Foresee Pharmaceuticals Co Ltd filed Critical Foresee Pharmaceuticals Co Ltd
Publication of CN112236142A publication Critical patent/CN112236142A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Addiction (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN201980009501.7A 2018-01-22 2019-01-21 用于缓释递送丁丙诺啡的药物组合物 Pending CN112236142A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862620317P 2018-01-22 2018-01-22
US62/620,317 2018-01-22
PCT/US2019/014422 WO2019144079A1 (en) 2018-01-22 2019-01-21 Pharmaceutical composition for sustained release delivery of buprenorphine

Publications (1)

Publication Number Publication Date
CN112236142A true CN112236142A (zh) 2021-01-15

Family

ID=67301573

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980009501.7A Pending CN112236142A (zh) 2018-01-22 2019-01-21 用于缓释递送丁丙诺啡的药物组合物

Country Status (9)

Country Link
US (1) US11419866B2 (https=)
EP (1) EP3743072B1 (https=)
JP (1) JP2021511326A (https=)
CN (1) CN112236142A (https=)
AU (1) AU2019209416A1 (https=)
CA (1) CA3089114A1 (https=)
ES (1) ES2965836T3 (https=)
TW (1) TW201936191A (https=)
WO (1) WO2019144079A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023246865A1 (en) * 2022-06-24 2023-12-28 Alar Pharmaceuticals Inc. Stable pharmaceutical composition of buprenorphine and preparation method and use thereof

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230080811A1 (en) * 2020-01-14 2023-03-16 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Long-acting ropivacaine pharmaceutical composition, preparation method therefor and use thereof
CN113117092A (zh) * 2020-01-14 2021-07-16 中国科学院上海药物研究所 一种非水缓释递药系统
WO2022175974A1 (en) * 2021-02-18 2022-08-25 Navin Saxena Research And Technology Private Limited Non-aqueous injectable composition for sustained release of buprenorphine and use thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0368409A2 (en) * 1988-11-10 1990-05-16 Norwich Eaton Pharmaceuticals, Inc. Compositions for the transdermal delivery of buprenorphine salts
CN101312730A (zh) * 2005-11-21 2008-11-26 谢尔英·普劳有限公司 包含丁丙诺啡的药物组合物
US20090270438A1 (en) * 2006-10-18 2009-10-29 Clive Booles Novel compositions and formulations
US20110230569A1 (en) * 2008-08-22 2011-09-22 Nistor Catalin Lipid formulations comprising a thiolated antioxidant
WO2012031252A1 (en) * 2010-09-03 2012-03-08 Abbott Laboratories High dose buprenorphine compositions and use as analgesic
US8236755B2 (en) * 2004-06-04 2012-08-07 Camurus Ab Opioid depot formulations

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8533582A (en) * 1981-07-10 1984-01-12 Reckitt & Colman Products Limited Stable solutions of buprenorphine
US4626539A (en) 1984-08-10 1986-12-02 E. I. Dupont De Nemours And Company Trandermal delivery of opioids
IT1302682B1 (it) 1998-10-16 2000-09-29 Formenti Farmaceutici Spa Composizioni farmaceutiche orali contenenti buprenorfina
DE60329515D1 (de) 2002-10-25 2009-11-12 Euro Celtique Sa Analoga und prodrugs von buprenorphin
CN1263760C (zh) 2002-11-12 2006-07-12 财团法人奇美医院 新颖的丁丙诺啡酯衍生物及其制备方法，以及长效作用镇痛药学组合物
EP2262367A4 (en) * 2008-03-08 2011-04-20 Theraquest Biosciences Inc PHARMACEUTICAL ORAL COMPOSITIONS OF BUPRENORPHINE AND METHOD FOR THEIR USE
WO2009148503A2 (en) 2008-05-30 2009-12-10 Namedepot.Com, Inc. Method and system for providing online services and software
GB2481018B (en) 2010-06-08 2015-03-18 Rb Pharmaceuticals Ltd Injectable flowable composition comprising buprenorphine
GB2481017B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
EP3791861A1 (en) 2012-07-26 2021-03-17 Camurus AB Opioid formulations
US9918981B2 (en) * 2013-09-10 2018-03-20 Insys Development Company, Inc. Liquid buprenorphine formulations
GB201404139D0 (en) * 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
NZ731309A (en) 2014-11-07 2022-02-25 Indivior Uk Ltd Buprenorphine dosing regimens

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0368409A2 (en) * 1988-11-10 1990-05-16 Norwich Eaton Pharmaceuticals, Inc. Compositions for the transdermal delivery of buprenorphine salts
US8236755B2 (en) * 2004-06-04 2012-08-07 Camurus Ab Opioid depot formulations
CN101312730A (zh) * 2005-11-21 2008-11-26 谢尔英·普劳有限公司 包含丁丙诺啡的药物组合物
US20090270438A1 (en) * 2006-10-18 2009-10-29 Clive Booles Novel compositions and formulations
US20110230569A1 (en) * 2008-08-22 2011-09-22 Nistor Catalin Lipid formulations comprising a thiolated antioxidant
WO2012031252A1 (en) * 2010-09-03 2012-03-08 Abbott Laboratories High dose buprenorphine compositions and use as analgesic

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
张晓军 等: "丁丙诺啡复方制剂治疗阿片类依赖研究进展", 《中国药物依赖性杂志》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023246865A1 (en) * 2022-06-24 2023-12-28 Alar Pharmaceuticals Inc. Stable pharmaceutical composition of buprenorphine and preparation method and use thereof

Also Published As

Publication number Publication date
EP3743072C0 (en) 2023-10-25
EP3743072A4 (en) 2021-09-22
US20200345724A1 (en) 2020-11-05
JP2021511326A (ja) 2021-05-06
AU2019209416A1 (en) 2020-07-30
ES2965836T3 (es) 2024-04-17
EP3743072A1 (en) 2020-12-02
EP3743072B1 (en) 2023-10-25
US11419866B2 (en) 2022-08-23
TW201936191A (zh) 2019-09-16
WO2019144079A1 (en) 2019-07-25
CA3089114A1 (en) 2019-07-25

Similar Documents

Publication Publication Date Title
US10517864B2 (en) Sustained-release buprenorphine solutions
ES2878112T3 (es) Formulación de implante de risperidona y/o paliperidona
KR102662530B1 (ko) 양극성 용매에서 안정한 치료 제형들의 제조방법.
CN112236142A (zh) 用于缓释递送丁丙诺啡的药物组合物
MX2014000454A (es) Nueva composicion terapeutica que contiene ingrediente activo de apomorfinas.
EA029921B1 (ru) Депо-композиция палиперидона с замедленным высвобождением, способ ее получения и способ психиатрического лечения с использованием этой композиции
JP7001584B2 (ja) 安定化されたグルカゴン溶液
KR20170072237A (ko) 주사가능한 부프레노르핀 제형
JP6356873B2 (ja) タキサン系活性成分含有液体組成物及び液体製剤
KR101892797B1 (ko) 향상된 안정성을 갖는 척수강내 히드로모르폰 용액
US20160058724A1 (en) Baclofen formulations and methods for making same
US10772895B2 (en) Pharmaceutical composition
TWI905111B (zh) 含有對硼苯基丙胺酸之注射液劑
JP2018530597A (ja) フルベストラント組成物
KR20220062368A (ko) p-보로노페닐알라닌을 함유하는 주사액제의 석출 방지 방법
KR20250099117A (ko) 도파민을 포함하는 약학적 주사용액
HK40081665A (en) Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents
TW201922278A (zh) 持續釋放之胜肽調配物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210115

WD01 Invention patent application deemed withdrawn after publication